How to Choose a Research Peptide Supplier in the UK: 12-Point Checklist

Choosing a research peptide supplier in the UK is a quality-assurance decision, not a shopping decision. A laboratory-grade supplier proves identity and purity for the exact batch in your hand, states the research-use-only basis of supply in writing, and controls the cold chain from lyophilisation to your door. This guide sets out a 12-point checklist you can apply to any vendor, the red flags that predict problems, and the UK legal framework that sits behind it all.

Updated 10 September 2026~14 min readReviewed by the GenoPept technical team

What makes a good research peptide supplier?

A good research peptide supplier is one that can answer, for the specific vial you received, three questions with documents: what is it, how pure is it, and how was it handled. Everything else — website design, catalogue breadth, delivery speed — is secondary to those three answers.

Research peptides are not commodity chemicals. They are synthetic products of a stepwise chemical process, and the impurity profile of a batch depends on the resin, the coupling efficiency at each residue, the cleavage cocktail and the purification gradient used that week. Two lots of the same sequence from the same factory can differ measurably.

Automated solid-phase peptide synthesis, reviewed comprehensively by Mäde and colleagues, builds a chain one residue at a time, and each incomplete coupling leaves a deletion sequence behind that must be resolved chromatographically.¹ That is precisely why batch-level documentation, rather than product-level marketing, is the meaningful signal.

The peptide field has also matured rapidly. Muttenthaler and co-authors count more than eighty approved peptide therapeutics worldwide and describe how modern analytical expectations followed that growth.² A supplier that has not adopted those expectations is operating on an older, weaker standard.

The 12-point supplier checklist

Work through the twelve points in order. The documentation block is a gate: if a supplier cannot produce a batch-specific certificate, the remaining nine points are irrelevant because you have no basis for believing the material is what the label says.

Documentation (points 1–3)

1. Per-batch certificate of analysis. Ask for the COA for the lot you will actually receive. A single PDF reused across every order tells you about a historical sample, not your vial.
2. Both HPLC and mass spectrometry. Reverse-phase HPLC answers “how much of this is one thing”; mass spectrometry answers “is that one thing the right molecule”. Purity without identity is meaningless — a 99% pure wrong sequence is still wrong.
3. Batch traceability. The lot code on the vial must appear on the certificate. Suppliers who publish an open COA library make this trivially checkable.

Product (points 4–6)

1. An intact lyophilised cake. Properly freeze-dried material forms a coherent puck or a fine even film. A collapsed, sticky or oily residue suggests the cake melted back in transit or the lyophilisation cycle was poor.
2. A stated mass basis. Does “5 mg” mean 5 mg of gross lyophilisate or 5 mg of net peptide? Good suppliers say which, and report net peptide content where the assay has been run.
3. Sealed, crimped vials. A butyl stopper under an aluminium crimp with an intact flip-cap is the only closure that supports repeated sterile withdrawal.

Legal (points 7–9)

1. A written research-use-only policy. Not a footer line — a policy page, plus an attestation step at checkout.
2. No medical or efficacy claims. Any supplier telling you what a compound will do to a person has stepped outside research supply, and the rest of their compliance is likely to be equally loose.
3. Correct handling of controlled substances. A small number of items — somatropin and chorionic gonadotrophin among them — sit inside the UK controlled-drug framework and should be flagged as such rather than sold as ordinary catalogue lines.

Service (points 10–12)

1. UK dispatch. Domestic stock removes border delay and shortens the ambient-temperature window a lyophilisate spends in transit.
2. A reachable technical contact. You should be able to ask a specification question and receive a specific answer.
3. Protective packaging and a replacement policy. Glass breaks. What matters is whether the supplier replaces the vial and reissues documentation without argument.

Certificates of analysis: what to demand

A certificate of analysis is the single most informative document in research peptide supply. It should carry, at minimum, product name and sequence, batch or lot number, manufacturing and retest dates, appearance, HPLC purity with the chromatogram, and an observed mass from mass spectrometry compared with the theoretical mass.

The chromatogram matters as much as the headline number. A clean trace with one dominant peak and a flat baseline supports a high purity figure; a trace with a large shoulder on the main peak may reflect a closely eluting deletion or oxidation product that a simple area-percent calculation flatters.

Purity is not the same as peptide content

Two numbers are routinely confused. Chromatographic purity is the percentage of the peptide-containing material that is the target sequence. Net peptide content is the percentage of the total lyophilised mass that is peptide at all, with the remainder being counter-ions from the purification step, residual solvent and bound water.

Both numbers can be correct at once. A vial can be 99% pure by HPLC and 80% peptide by mass, which means a nominal 5 mg vial holds around 4 mg of actual peptide. This is not fraud; it is the normal chemistry of a trifluoroacetate or acetate salt form. It becomes a problem only when a supplier hides it, or when a researcher builds molar calculations on the gross mass without adjusting.

The supply chain behind a vial

Understanding the chain in Figure 2 tells you which questions are worth asking. Synthesis quality determines the impurity profile; purification determines how much of that profile survives; lyophilisation determines physical stability; and the cold chain determines whether any of that work is preserved by the time the vial reaches you.

Lyophilisation is the step most often underestimated. Removing water by sublimation under vacuum converts a solution into an amorphous solid in which molecular mobility is low and the classic degradation reactions run far more slowly. Manning and colleagues catalogue those reactions in detail — deamidation of asparagine and glutamine, oxidation of methionine and cysteine, hydrolysis at labile bonds, and physical aggregation — and note that all of them accelerate in solution relative to the dry state.³

That is why a properly formed cake matters and why the recommended handling for an unopened lyophilised vial and a reconstituted solution are so different. Our companion pieces on peptide storage and reconstitution technique go further into that.

The UK legal framework in plain terms

Research peptides sit in a specific legal position in the UK. Most are not controlled drugs and not licensed medicines; they are chemicals supplied for laboratory use. The framework that constrains supply has three separate strands, and it is worth understanding which one applies to which situation. This is general information, not legal advice.

Medicines law

The Human Medicines Regulations 2012 govern anything presented as a medicinal product. Regulation 17(1) states that a person may not, except in accordance with a manufacturer’s licence, “manufacture, assemble or import from a state other than an EEA State any medicinal product”.⁴ The trigger is presentation and purpose: a substance marketed with claims about treating or preventing disease is being presented as a medicine, whatever the label says. This is exactly why research-use-only framing is a legal necessity rather than a stylistic preference.

Controlled drugs

A small number of hormone products fall under the Misuse of Drugs framework. The Misuse of Drugs Act 1971 (Modification) Order 1996 added a group of anabolic and androgenic steroids and polypeptide hormones to the Class C list.⁵ Schedule 4 Part II of the Misuse of Drugs Regulations 2001 lists, among others, “Chorionic Gonadotrophin (HCG) … Non-human chorionic gonadotrophin … Somatotropin … Somatrem … Somatropin”.⁶ Products in that schedule are Class C controlled drugs, and while Part II placement carries an exemption from the possession offence, supply and importation remain regulated activities.

Trading standards and consumer law

General consumer protection and product-description law applies to every sale. A supplier who describes a product inaccurately — wrong sequence, overstated purity, invented testing — is exposed under that law independently of anything in medicines or drugs legislation.

Red flags and green flags

Warning signs in this market are unusually consistent. In practice they cluster: a supplier that omits batch documentation almost always also uses human-facing language, and almost never publishes a company address. Table 2 pairs the most common failure signals against what a competent supplier does instead.

Shipping, cold chain and UK dispatch

Lyophilised peptides are considerably more robust than solutions, which is why short ambient-temperature transit is normally tolerable. The risk is not a warm afternoon in a van; it is a fortnight in an unrefrigerated customs facility followed by another week of onward delivery.

Domestic dispatch removes that exposure. It also removes the buyer’s border risk entirely: goods that never cross a border cannot be detained at one. When comparing an overseas supplier at a lower headline price against a UK-held equivalent, the honest comparison includes transit time, replacement risk and the value of the batch documentation you can actually obtain afterwards.

On arrival, three checks take under a minute. Is the vial intact and the crimp seal unbroken? Is the cake coherent rather than melted or oily? Does the lot code on the label match a certificate you can retrieve? If all three pass, transfer the vial to storage per its specification and record the lot against your experiment.

How GenoPept maps to the checklist

Stated factually and without claims: GenoPept is UK-based and dispatches from the UK. Products are supplied as lyophilised vials. Each batch carries a third-party certificate of analysis covering HPLC purity and mass-spectrometry identity, and those certificates are published at the COA library so a lot code on a vial can be reconciled against its document.

Supply is on a research-use-only basis under a published Research Use Only policy, with an attestation step at checkout. Dispatch and packaging arrangements are set out on the shipping information page, and tiered pricing for larger quantities is described under bulk and wholesale. Where a catalogue item sits inside the UK controlled-drug framework — somatropin is the clearest example — that status is stated rather than glossed over.

Apply the same twelve points to any supplier, including this one. A checklist that only one vendor can pass is a marketing device; a checklist that any competent vendor can pass is a standard.